Liquidia (LQDA) Income from Continuing Operations (2020 - 2026)

Liquidia's (LQDA) quarterly Income from Continuing Operations came in at 52882000.0 in Q1 2026, up 237.83% year-on-year from 15653342.91 in Q1 2025, and up 263.33% quarter-over-quarter from 14555000.0 in Q4 2025.

Liquidia (LQDA) Income from Continuing Operations (2020 - 2026) Analysis & Trends

Liquidia's Income from Continuing Operations history runs 7 years deep, the most recent figure standing at 52882000.0 for Q1 2026.

  • On a quarterly basis, Income from Continuing Operations rose 237.83% year-over-year to 52882000.0 in Q1 2026; TTM through Mar 2026 was 186865000.0, a 23.86% increase from a year earlier, with the FY2025 full-year figure at 293685000.0, down 28.44% from the prior year.
  • Income from Continuing Operations grew to 52882000.0 in Q1 2026 per LQDA's latest filing, from 14555000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 52882000.0 in Q1 2026 and bottomed at 149910000.0 in Q3 2025.
  • The 5-year median for Income from Continuing Operations is 31183000.0 (2023), against an average of 43945352.94.
  • Across the five-year window, Income from Continuing Operations slumped 293.38% in 2024 and soared 237.83% in 2026, its largest moves.
  • Year by year, Income from Continuing Operations stood at 6533000.0 in 2022, then sank by 229.66% to 21537000.0 in 2023, then slumped by 78.81% to 38510000.0 in 2024, then jumped by 137.8% to 14555000.0 in 2025, then soared by 263.33% to 52882000.0 in 2026.
  • Per Business Quant, the three latest LQDA Income from Continuing Operations figures stand at 52882000.0 (Q1 2026), 14555000.0 (Q4 2025), and 149910000.0 (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Income (Continuing) (Qtr)
1 Haleon 87.22 Bn 85.35 Bn - -
2 Teva Pharmaceutical Industries 39.60 Bn 35.87 Bn 1.97 Bn 370.00 Mn
3 Zoetis 31.46 Bn 29.52 Bn 1.62 Bn 601.00 Mn
4 Takeda Pharmaceutical 26.49 Bn 22.44 Bn 4.39 Bn -3.58 Bn
5 United Therapeutics 23.03 Bn 20.88 Bn 648.10 Mn 274.90 Mn
6 Universe Pharmaceuticals 23.03 Bn -10.56 Bn - -
7 Viatris 20.90 Bn 19.09 Bn 1.16 Bn 176.40 Mn
8 Neurocrine Biosciences 17.50 Bn 16.19 Bn 800.70 Mn 197.90 Mn
9 Elanco Animal Health 12.33 Bn 11.91 Bn 785.00 Mn 57.00 Mn
10 Liquidia 7.84 Bn 7.61 Bn 121.79 Mn 52.88 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 52.88 Mn
Dec 31, 2025 14.56 Mn
Sep 30, 2025 -149.91 Mn
Jun 30, 2025 -104.39 Mn
Mar 31, 2025 -38.37 Mn
Dec 31, 2024 -38.51 Mn
Sep 30, 2024 -75.21 Mn
Jun 30, 2024 -93.32 Mn
Mar 31, 2024 -121.96 Mn
Dec 31, 2023 -21.54 Mn
Sep 30, 2023 -31.18 Mn
Jun 30, 2023 -53.03 Mn
Mar 31, 2023 -31.00 Mn
Dec 31, 2022 -6.53 Mn
Sep 30, 2022 -19.38 Mn
Jun 30, 2022 -14.35 Mn
Mar 31, 2022 -15.82 Mn
Dec 31, 2021 -11.56 Mn
Sep 30, 2021 -13.74 Mn
Jun 30, 2021 -7.96 Mn